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ABSTRACT 
Phenazines and heterocyclic N-oxides have proven to be interesting classes of antitumoral as well 
as antibiotic agents . The natural product myxin (1-hydroxy-6-methoxyphenazine- N5, N10-dioxide) 
which belongs to both of these unique classes of molecules, has been found to cause bio-reductively acti-
vated, radical-mediated DNA strand cleavage via a de-oxygenative mechanism, making it a potential anti-
tumoral as well as anti-bactierial candidate. In order to investigate as well as improve the bioactive prop-
erties of myxin, the following study was designed to synthesize glycosylated myxin analogs. A small cat-
alog of these compounds were synthesized, some of them exhibiting comparable biological activity to that 
of myxin.  
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1 INTRODUCTION  
Phenazines are a class of naturally occurring compounds that are comprised of a nitrogen contain-
ing, heterocyclic moiety that vary in both their chemical and physical properties based on the type and 
position of substituents present. More than 100 different phenazine structural derivatives have been iden-
tified in nature, bacteria being the only source of these natural compounds, and over 6000 compounds that 
encompass phenazine as the central moiety have been synthesized.1 Phenazine natural products are isolat-
ed as secondary metabolites from bacterial genera such as Pseudomonas, Streptomyces, and other genera 
from soil and marine habitats. 2 Both natural and synthetic phenazines have been of particular interest due 
to the fact that they have been known to exhibit an extensive range of biological activities including 
antitumoral , antibiotic, and anti-parasitic properties.2-3 While the physiological function of naturally oc-
curring phenazines have yet to be fully understood, their mode of action has been proposed to include 
biological targets such as polynucleotide interactions, inhibition of topoisomerase I and/or II, and free-
radical scavenging.4 The polynucleotide interacting phenomena exhibited by many phenazines such as 
pyocyanin(1), iodinin (2), and myxin (3) stems from their planar and aromatic structure which is compa-
rable to known intercalators such as daunomycin, chromomycin, and ethidium bromide.5  
 
              
Figure 1.1 Phenazines: Pyocyanin (1), Iodinin (2), Myxin (3) 
 
These respective structural characteristics allow for π-π interactions between the phenazines and 
the base pairs of DNA, which in turn allows them to intercalate. In addition, phenazines 1,2 and 3 have 
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been shown to also bind to either base pairs in double stranded DNA, RNA polymerase, and/or to 
ribonucleoside 5’-triphosphate.2 Although, there has yet to be any naturally occurring phenazine that in-
hibits topoisomerase to date, many synthetic phenazine analogs have been synthesized that have shown 
inhibition of topoisomerase I/II.6  This particular strategy consisting of the target of the topoisomerase 
enzymes stems from the fact that proliferating cells, like cancer cells contain large concentrations of 
topoisomerases.2 Phenazines have also displayed antibiotic activity through radical scavenging phenome-
na. Certain phenazines such as 1 have been shown to generate radicals that when inside cells, can accept 
electrons and thereby interrupt electron transport and respiratory flow in the cell.2  
One particular phenazine that has reemerged as a compound of interest due to its antitumoral 
properties, and for which the following study is based upon is that of 3 (1-hydroxy-6-methoxyphenazine- 
N5, N10-dioxide, or myxin). Myxin, a natural product, was first isolated from Sorangium sp. By Peterson 
et al. in 1966.7 The uniqueness of myxin is of interest due to the fact that it not only belongs to the class 
of phenazine compounds, but also to a class known as heterocyclic N-oxides. Heterocyclic N-oxides have 
been known to be an attractive class of compounds that exhibit antitumor and antibacterial agency 
through their bio-reductively activated, hypoxia-selective DNA-damaging properties.8 Many studies that 
have investigated the bio-reductive properties of heterocyclic N-oxides have been based off of a lead 
compound known as tirapizamine (TPZ, 4, Figure 1.2), which has been investigated in phase I, II, and III 
of clinical trials for the treatment of various cancers.9 The hypoxia-selective cytotoxicity of TPZ and other 
compounds in the respective class of compounds lies in its ability to undergo an intracellular one-electron 
reduction mechanism (5, Figure 1.2) followed by a deoxygenative mechanism to form a key DNA dam-
aging intermediate (7, Figure 1.2) and other metabolite byproducts (6, Figure 1.2).10 In the presence of 
molecular oxygen, the radical intermediate is back oxidized to the parent molecule and does not proceed 
through the DNA-damaging intermediate (Figure 1.2).  
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Figure 1.2 Bio-reductive Mechanism of Tirapazamine (TPZ) 
 
 
The use of TPZ in a clinical setting has been limited in the fact that it has exhibited poor extra-
vascular support and thus has lead researchers to investigate similar heterocyclic N-oxides with improved 
activity.11 Myxin (3) however, causes bio-reductively activated, radical-mediated DNA strand cleavage 
under both aerobic and anaerobic conditions via a deoxygenative mechanism analogous to that character-
ized for tirapazamine under anaerobic conditions (Figure 1.3).10 This observation has led to biological 
activity comparisons drawn between myxin and TPZ that have shown that myxin has comparable activity 
to that of TPZ in anaerobic conditions and improved activity in aerobic conditions.10 The fact that myxin 
is active under both of these conditions exhibits its potential antibacterial as well as anti-tumoral potential. 
It has been suggested that myxin’s aerobically active properties lie within the fact that the radical anion 
(8) possesses phenoxyl radical characteristics. This intermediate, which is generated following the enzy-
matic one electron reduction of myxin (3) has been hypothesized to be more stable and thus less sensitive 
to oxygen, which in turn allows the intermediate to proceed through the reductive mechanism and gener-
ate DNA damaging radicals.10 Therefore, myxin’s double agency in the phenazine class as well as the 
heterocyclic N-oxide class has rendered it as an interesting compound of interest in the fields anticancer 
and antibacterial research.  
In order to investigate further improvements of the biological activity of myxin along with its 
other analogs, the synthesis of glycoside conjugates of myxin analogs was proposed. Carbohydrates car-
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rying an aromatic aglycon have proven to be very important compounds with examples such as antibiotics 
such as vancomycin and chromomycin.12 An increase in the understanding of the important roles that 
glycoconjugates play in biological processes has led to a demand for these respective compounds in me-
dicinal and pharmacological studies.13 In light of these observations, the synthesis of glycosylated myxin 
analogs was carried out in order to investigate the effect that conjugated glycosides had on the bioactivity 
of myxin analogs. In addition to the glycosylation of 3, the glycosylation of compound 9 was also of in-
terest due to the fact that previous studies observed that it had significantly lower bioactivity than its pre-
cursor, 10 under both aerobic and anaerobic conditions.10 Chowdury et al. suggest that 9 may engage in 
redox cycling similar to that of 4, but that the radical anion is incapable of being further reduced allowing 
for the release of its own cytotoxic species i.e. the hydroxyl radical.10 However, this “ease of reduction” 
of compound 9 may be improved by the addition of acetylated glycosides, which in turn increases the 
electrophilic nature of the aromatic system and thus stabilizes the radical anion.14  
 
 
Figure 1.3 Bio-reductive Mechanism of Myxin 
 
 
The chemical synthesis of glycosides typically involves the transformation of a particular sugar 
into a fully protected glycosyl donor with a leaving group at its anomeric center.13 These leaving groups 
can encompass a list of potential functional groups such as halides, acetates, trifluroacetates, and 
trichloroacetimidates (Figure 1.4).12 
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Figure 1.4 Examples of Acetylated Glucoside Donors 
 
Glycosylation of a suitably protected glycosyl acceptor, which generally contains a free hydroxyl 
group, then is carried out. The glycosyl donor can be viewed as “transferring” the glycosyl moiety (which 
is generally an electrophile) to the glycosyl acceptor (which is generally a nucleophile). Therefore, the 
leaving group as well as the protecting groups are the main fundamental parameters with respect to the 
yield and anomeric selectivity of glycosylation reactions.13 However, there are many problems associated 
with the glycosylation of phenol groups such as that in compounds such as 3 and 9. Some of these diffi-
culties include the fact that phenols are considered weak nucleophiles, and sensitivity to pH.12 Due to the 
stereo-selectivity, ease of use, and strong electrophilic characteristics of glycosyl halides, glycoside bro-
mide was selected as the “donor” and compounds 3 and 9 along with other myxin analogs were selected 
as the “acceptors.” This Koenigs- Knorr method encompassed the use of various phase transfer catalysts 
under basic conditions, which were utilized in these glycosylation reactions in order to obtain an optimal 
yield. Due to the potential improved solubility as well as more positive reduction potential of 9, it was 
hypothesized that the myxin analogs such as 9 would exhibit improved bioactivity following their conju-
gation with different acetylated glycosides.  
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2    METHODOLOGY 
In the process of chemically synthesizing  the central phenazine moiety found in compound 3,  
many modifications to the synthetic routes reported by Chowdury et al. were made.10 All synthetic 
routes were scaled up to yield larger quantities of the respective product. All materials were pur-
chased at the highest possible purity from Sigma Aldrich Chemical Company. Of the various synthet-
ic routes that could have been carried out in the generation of 3 and its precursors, only the route that 
included the cleavage of a single methoxy group in the 1,6-dimethoxy phenazine compound prior to 
its oxidation was carried out habitually (Figure 2.1). The glycosylation of 9 was carried out using 
modifications to glycosylation techniques described by Wu et al (Figure 2.2).15 In the synthesis of 6-
methoxyphenazine-1-β-D- glycosides, only the glucose analog of the unacetlayed compound was syn-
thesized. All 1H NMR, 13C NMR, and ESI mass spectra are provided in the appendix.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Synthetic Scheme of Myxin 
 
7 
 
 
Figure 2.2 Synthesis of 6-Methoxyphenazine-1-β-D- glycosides 
 
2.1 Synthesis of 1,6-Dimethoxyphenazine 
 
                            
Figure 2.3 Synthesis of 1,6-Dimethoxyphenazine 
 
1,6- Dimethoxyphenazine was synthesized by first adding 0.80 mol (90.22 mL) of o-anisidine to 500 
mL of anhydrous benzene. 1.44 mol (176 mL) of o-nitroanisole  along with 4 mol (224.42 g) of powdered 
potassium hydroxide was then added to the solution. The solution was heated at reflux for 8 hours with 
vigorous stirring. Upon cooling overnight, the benzene solution was decanted off and cold water was add-
ed to the reaction flask in order to break up the solid and extract any remaining potassium hydroxide. The 
solid was then collected via vacuum filtration and washed twice with ethanol. After filtration, the solid 
was recrystallized using hot ethanol and dried with an oil pump to yield 14% of product. Rf = 0. 50 (100% 
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ethyl acetate) Spectra 1. 13C NMR Spectra 2.  Mass spectra (ESI) was also collected in order to verify the 
structure Spectra 3.   
 
2.2    Synthesis of 1-Hydroxy-6-methoxyphenazine 
 
 
Figure 2.4 Synthesis of 1-Hydroxy-6-methoxyphenazine 
 
1-Hydroxy-6-methoxyphenazine was made by adding 0.064 mol (16.21 g) of 1,6 
dimethoxyphenazine to 300 mL of dichloromethane in a 500 mL round bottom flask. Then 0.351 mol 
(43.46 g) of aluminum chloride was added to the solution under 0˚C condition and allowed to stir for 20 
minutes. The progression of the reaction was verified through TLC analysis using 5:1 ethyl acetate to 
hexane, Rf = 0.63. The mixture was then worked up by adding solution to 0.5 N HCl in order to quench 
the mixture, followed by extraction with dichloromethane. Product was then further purified using silica 
gel column chromatography (1:1 ethyl acetate to hexane). Percent yield = 17%. 1HNMR Spectra 4. 
13CNMR Spectra 5. MS (ESI) Spectra 6.  
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2.3 Synthesis of Myxin (1-Hydroxy-6-methoxyphenazine-N5, N10-dioxide) 
                
 
Figure 2.5 Synthesis of Myxin  
 
To a solution of 0.0044 mol (1.0 g) of 1-Hydroxy-6-methoxyphenazine in 50 mL of dichloro-
methane was added 3.0 g of m-CPBA. The mixture was stirred at room temperature for 12 hours and 
evaluated by TLC using 2:1 hexane to ethyl acetate Rf = 0.63 for compound 3 and 0.45 for compound 
9. Mixture was then worked up by diluting with another 100 mL of DCM and washed with 5% 
Na2SO3, NaHCO3 and brine washes were then followed by drying with Na2SO4. Products were sepa-
rated via silica column using 1/3/1 ethyl acetate/hexane/DCM yielding 75% of compound 9 and 
5.31% of compound 3. For compound 3, 1H NMR Spectra 7. 13CNMR Spectra 8. Product was also 
evaluated using mass spectrometry (ESI) Spectra 9. For compound 9, 1H NMR Spectra 7a. 
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2.4 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide 
 
             
Figure 2.6 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide 
 
The synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide was carried out by adding 8 mL 
of 33% HBr in acetic acid to 1 g (2.60 x 10-3 mol) of β-D-glucose pentaacetate under nitrogen at 0°C. Af-
ter 5 minutes, the solution was allowed to stir to completion at room temperature (Rf = 0.35 1:1, 1 hexane: 
1 ethyl acetate). Upon completion of the reaction, the solution was diluted with 60 mL of dichloro-
methane and 30 mL of cold H2O. The organic layer was collected and washed with NaHCO3 until the 
aqueous layer was at a pH of 7. 90% of product was yielded. 1HNMR Spectra 10. 13CNMR Spectra 11. 
MS (ESI) Spectra 12. 
 
2.5 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
 
                   
Figure 2.7 Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
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The synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide was carried out by adding 8 
mL of 33% HBr in acetic acid to 1 g (2.60 x 10-3 mol) of β-D-galactose pentaacetate  under nitrogen at 
0°C. After 5 minutes, the solution was allowed to stir to completion at room temperature (Rf = 0.35 1:1, 1 
hexane: 1 ethyl acetate). Upon completion of the reaction, the solution was diluted with 60 mL of di-
chloromethane and 30 mL of cold H2O. The organic layer was collected and washed with NaHCO3 until 
the aqueous layer was at a pH of 7. 87% of product was yielded. 1HNMR Spectra 13. 13CNMR Spectra 
14. MS (ESI) Spectra 15. 
 
2.6 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside 
 
 
Figure 2.8 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside 
 
113 mg (5.00 x 10-4 mol) of 1-hydroxy-6-methoxyphenazine along with 410 mg of 2,3,4,6-Tetra-
O-acetyl-α-D-galactopyranosyl bromide (1.05 x 10-3mol) was dissolved in 8 mL of CHCl3. 8 mL of 
H2O was then added along with 138 mg (1.00 x 10-3 mol) of K2CO3 to the mixture. A catalytic 
amount of tertbutylammonium iodide (PTC A)/tertbutylammonium bromide (PTC B)/aliquat 336 
(PTC C) was added to the mixture. The reaction was allowed to stir at 50.0° C for 24 hours. The reac-
tion temperature was then decreased to room temperature and the reaction was allowed to stir for an 
additional 12 hours. After completion of the reaction, the reaction mixture was worked up by adding 
0.1 M HCl and extracting the organic layer. The organic layer was further washed with brine and 
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once again extracted. The final compound was purified via column with 1:1, hexane: ethyl acetate. Rf 
= 0.21 using 1:1, hexane: ethyl acetate. Percent yield with PTC A and PTC B was only trace amounts. 
Percent yield with PTC C was 75%.  1HNMR Spectra 16. 13CNMR Spectra 17. MS (ESI) Spectra 18.  
 
2.7 Synthesis of 6-methoxyphenazine-N10-oxide-beta-D-tetraacetylgluco-pyranoside 
             
 
Figure 2.9 Synthesis of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside 
 
The synthesis of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside was carried 
out by dissolving 50 mg of 6-methoxyphenazine-N5-oxide-beta-D-tetraacetylgluco-pyranoside (8.73 
x 10-5 mol) in dichloromethane. 0.106 g of m-CPBA (6.14 x 10-4 mol) was then added to the solution 
and the solution was allowed to stir for 24 hours under argon at room temperature. Over the course of 
the reaction, the solution gradually turned from yellow to orange. After completion of the reaction, 
the organic layer was diluted with dichloromethane and washed with NaHCO3 followed by brine. The 
product was purified by column using 1:1, hexane: ethyl acetate. Rf = 0.67 using 100% ethyl acetate. 
Yielded 90% of product. 1HNMR Spectra 19. 13CNMR Spectra 20. MS (ESI) Spectra 21.  
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2.8 Synthesis of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside 
 
 
Figure 2.10 Synthesis of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside 
  
10 mg (2.47 x 10-5 mol) of 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside was dis-
solved in a mixture of 6 mL of anhydrous methanol and 1 mL dichloromethane. A small amount so-
dium methoxide was then added, and the solution was allowed to stir at room temperature for one 
hour. After completion of the reaction, Amberlyst 15H form was added to the solution carefully, until 
the solution reached a pH of 7. Solution was diluted further with methanol and evaporated. Rf = 0.25 
using 10: 1, dichloromethane: methanol. Yielded 99% of product. 1HNMR Spectra 22. 13CNMR 
Spectra 23. MS (ESI) Spectra 24.   
 
 
 
 
 
 
14 
 
2.9 Synthesis of 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside 
 
 
Figure 2.11 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside 
 
200 mg (8.84 x 10-4 mol) of 1-hydroxy-6-methoxy phenazine was dissolved in a 8 mL CHCl3/8 
mL H2O mixture. 800 mg (2.05 x 10-3 mol) of 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
was then added to the solution. 276 mg of K2CO3 was then added to the solution followed by a cata-
lytic amount of either PTC A (tetrabutylammonium iodide), PTC B (tetrabutylammonium bromide), 
or PTC C (aliquat 336). The solution was allowed to stir under nitrogen for 24 hours at 50°C. After 
completion of the reaction, the solution was diluted with 30 mL of dichloromethane. Solution was 
then worked up by first adding 30 mL of 0.1 M HCl and then extracting the organic layer. Product 
was purified by column using 2:1, hexane: ethyl acetate. Rf = 0.25 using 1:1, hexane: ethyl acetate. 
When using both PTC’s A and B, the percent yield was only in trace amounts. PTC C yielded 80%. 
1HNMR Spectra 25. 13CNMR Spectra 26. MS (ESI) Spectra 27. 
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2.10 Synthesis of 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside 
 
 
Figure 2.12 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside 
 
Dissolved 50 mg (9.00 x 10-5 mol) of 6-methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside 
in 10 mL of dichloromethane. Added 100 mg (5.80 x 10-4) of m-CPBA to the reaction mixture and al-
lowed to stir at room temperature for 24 hours. Over the course of the reaction, the solution turned 
from yellow to orange. After completion of the reaction, the organic layer was diluted with dichloro-
methane and washed with NaHCO3 followed by brine. The product was purified by column using 1:1, 
hexane: ethyl acetate. Rf = 0.67 using 100% ethyl acetate. Yielded 90% of product.  1HNMR Spectra 
28. 13CNMR Spectra 29. MS (ESI) Spectra 30.  
 
2.11 GI50 Assay 
 
Cancer cell lines HCT-8 (colon cancer cells), HeLa (immortalized cervical cancer cells), 
AGS (gastric cancer cells), MCF-7 (breast cancer cells), and HepG2 (liver cancer cells) were 
kindly provided by Dr. Jin-Xiong She of Georgia Regents University. The cancer cell line 
Molt-4 (acute lymphoblastic leukemia) was kindly provided by Dr. Binghe Wang of Georgia 
State University. HCT-8, Hela, AGS and Molt-4 cancer cells were cultured in RPMI 1640 
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medium with 10% Fetal Bovine Serum and 1% of the respective drug target. MCF-7 and 
HepG2 cancer cells were cultured in DMEM medium with 10% Fetal Bovine Serum and 1% 
respective drug target. All cells were incubated in 5% CO2 at 37˚C and were given medium 
and plate changes as needed. The evaluation of 50% growth inhibition (GI50) by prolifera-
tion assay was carried out by diluting HCT-8, HeLa, and AGS cells to a concentration of 3.5 
x 104 cells/mL and MCF-7, Molt-4, and HepG2 cells to a concentration of 4 x 105 cells/ml. 
100 µL of the cell suspension was seeded in 96 well plates. The plates were incubated in 5% 
CO2 at 37˚C overnight, giving ample time for adherent cell lines to adhere to the plates. The 
following day, 1 µL of the prepared compound dilutions (3-fold dilutions) was added to each 
well, so that the highest final concentration was 50 µM with 8 successive dilutions. Cells 
were then incubated for 72 hours.  A Dojindo CCK-8 kit was used to estimate the number of 
viable cells in each well according to the manufacturer’s instructions. After 4h incubation, 
OD values were measured at 450nm using the multifunctional microplate reader. The data 
was then analyzed to construct a GI50 curve and calculate the GI50 value using Sigmaplot 
software. Growth inhibition was calculated using the following formula: GI = (control OD– 
experimental OD)/control OD. 
 
3 RESULTS AND DISCUSSION 
The initial synthesis of compound 3 and its phenazine precursors (3a and 3b) proved successful. 
However, synthesizing desirable yields of these respective compounds proved challenging. This can 
be attributed to the fact that in each step of this synthesis, the desired compound was a minor product. 
An example can be considered compound 3b, which forms 1,6-dihydroxy phenazine as the major 
product. The glycosylation of compound 3b proved successful as well. These glycosylation reactions 
were carried out using the Koenigs- Knorr method, using K2CO3 as the weak base and various phase 
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transfer catalysts to improve the yield of the glycosylation product. In this process, it was determined 
that commercially available phase transfer catalyst PTC C gave an optimal yield of 75% of both the 
galactoside and glucoside products, while PTC A and PTC B gave minimal yields. Because acetyl 
glycoside bromides were utilized as the donor in the glycosylation reactions, only a β- linkage of the 
phenazine acceptor was formed, hence the selective capabilities of glycosyl bromides. Oxidation of 
the subsequent glycoside phenazines (compounds 10 and compound 13) only yielded  mono-oxide 
products (compounds 11 and 14).  This formation of exclusively mono-oxide products can be at-
tributed to the fact that the presence of the sugar “blocks” the oxidation of the N10 nitrogen by a ste-
ric effect. Chowdury et al describes an effect similar to this in previous experiments where the free 
hydroxyl group of the 1-hydroxy-6-methoxy phenazine compound was protected with a TBDPS 
group. In this study, it was found that the TBDPS group did indeed sterically hinder the oxidation of 
the N10 nitrogen and yielded the mono-N5-oxide as a major product.10 In the case where there is no 
sugar present, like in the formation of compound 3, previous studies suggest that the hydroxy group 
of the 1-hydroxy-6-methoxy phenazine compound directs the oxidation of the N10 nitrogen and thus 
yields compound 9 as a major product and compound 3 as a minor product. It also must be noted that 
the glycosylation of compound 3 using the Koenigs- Knorr method along with the various phase cata-
lysts proved unsuccessful. One potential reason for this could be the fact that the strength of hydrogen 
bond between the phenolic proton and “negatively charged” oxygen is too strong to be cleaved by a 
weak base such as K2CO3. Another reason could be simply due to a “steric effect” that arises from the 
N10-oxide that disrupts the nucleophilic character of the phenol. The same result was seen when 
compound 9 served as the acceptor (which comprised the N10 mono-oxide), in that glycosylation us-
ing the Koenigs- Knorr method was unsuccessful (Figure 3.2).  
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Figure 3.1 Attempted Glycosylation of 3b, 9, and 3 
 
Nonetheless, a small, initial catalog of novel glycosylated phenazines and heterocyclic N-oxides 
was created during these synthetic experiments (Figure 3.2). These compounds were then tested 
against various cancer cell lines including HeLa, Skov-3, HCT-8, HepG2, MCF-7, and Molt-4 and as-
sayed in a GI50 study.   
 
19 
 
N
N
OMe
O
O
AcO
OAc
OAc
AcO
10
N
N
OMe
O
O
AcO
OAc
OAc
13
OAc
N
N
OMe
O
O
AcO
OAc
OAc
O
AcO
11
N
N
OMe
O
O
AcO
OAc
OAc
O
14
OAc
N
N
OMe
O
O
HO
OH
OH
O
HO
12
 
Figure 3.2 Novel Glycosylated Compounds 
 
The GI50 study was carried out under a oxygenated environment meaning that the following com-
pounds were assayed under aerobic conditions. All compounds in the assay were tested at a concen-
tration of 50 µL. For the sake of comparison of the biological activity of compounds 10- 14, doxoru-
bicin (a commercial drug known for its high toxicity by intercalation), and compound 4 
(tirapazamine, TPZ) were also included (Table 3.1). Due to the fact that the GI50 assay was carried out 
under aerobic conditions, it would be expected that compound 4 would not show any significant 
bioactitivty based off the mechanism explained in Figure 1.2. Based off the GI50 values, compounds 
11 and 14 exhibited improved bioactivity than compounds 4 and 9 and showed comparable bioactivi-
ty with compound 3 when tested with Hela and Skov-3 cell lines. When tested with cell lines HCT-8, 
MCF-7, and Molt-4, compounds 11 and 14 exhibited only improved bioactivity than compounds 4 
and 9. When the glycosylated compounds that were absent of the N-oxide moiety (compounds 10 and 
13) were tested in all cell lines, there was no sign of improved bioactivity in comparison to com-
pounds 3, 4, and 9. It also must be noted that compound 12, which contained the unacetylated 
glucoside, N-oxide moiety exhibited no signs of improved bioactivity in comparison to compounds 3, 
4, and 9.  
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Possible explanations for the increased activity of compounds 11 and 14 in comparison to 4 and 9 
can be attributed to the fact that the presence of the acetylated sugar increases the electrophilic nature 
of the overall molecular structure, which in turn increases its reduction potential, stabilizing the radi-
cal anion after its reduction. Another explanation of the improved bioactivity of these respective 
compounds can be due to the improved uptake of 11 and 14 into the cells due to improved solubility. 
However, it must be noted that compound 9 has the N10 oxidized and compounds 11 and 14 have the 
N5 oxidized, so direct comparisons cannot necessarily draw an exact conclusion to this difference in 
activity. Nonetheless, the comparison of compounds 9 against compounds 11 and 14 can still give 
clues into improving the activities of mono-N-oxide phenazines, which have shown significantly less 
bioactivity than myxin and tirapazamine overall.10  The lack of improvement in bioactitivty in com-
pounds 10 and 13 against compounds 3, 4, and 9 most likely can be attributed to the lack of the N-
oxide moiety and thus not allowing for any degree of reduction, which would in turn allow for pro-
duction of DNA damaging radicals. This result therefore, is in agreement with early hypotheses. Fi-
nally, compound 12’s lack of improved bioactivity vs. compound 11 can most likely be attributed to 
better uptake of an aceylated glucose as opposed to a free glucose in the structure. It can be predicted 
that glucose that is protected with acetyl groups can cross through the cell membranes more readily 
than unprotected glucose. 
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Table 1 GI50 Assay (µM) 
 
 
4     CONCLUSION 
 
Although the glycosylation of compounds 3 and 9 were deemed unsuccessful using the Koenigs- 
Knorr method, successful synthesis of glycosylated non-oxidized phenazines using the same method were 
indeed successful (10, and 13). Further studies within the glycosylation of heterocyclic-N-oxides will in-
clude investigating different glycosylation techniques utilizing other carbohydrate donors such as 
glycosyl trichloroacetimidates and thioglycosides. Due to the fact that β-linkaged glycosides were synthe-
sized, future studies will also include the synthesis of α-linkaged glycosides as well. In addition, in order 
to further study myxin’s bioactive properties in the field of cancer and antibiotics, functionalization with 
various halogen and alkyl groups will also be carried out. The GI50 results of compounds 11 and 14 point 
to potential retained biological activity and thus allow for these compounds’ further study within the ap-
plicative field of phenazines and heterocyclic- N-oxides. Ongoing studies of these compounds include 
many aspects including specific mechanisms of action. In order to study these mechanisms of action, ad-
Compound Hela Skov3 HCT-8 HepG2 MCF-7 Molt-4 
4 52.19 67.94 249.49 89.42 237.72 90.41 
Doxorubicin <0.22 <0.22 3.50 <0.22 0.01 <0.22 
3 17.2 12.0 53.83 19.42 31.84 5.08 
9 469 125.27 180.63 98.71 308.76 29.16 
11 24.19 120.89 >100 >100 195.07 17.79 
14 18.79 17.00 96.25 141.85 122.97 17.40 
10 >100 >100 >100 >100 >100 17.40 
13 >100 >100 >100 >100 >100 21.67 
12 >100 >100 >100 >100 >100 33.63 
3a >100 >100 >100 >100 >100 >100 
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ditional assays including DNA cleavage tests (which would give further clues into whether these com-
pounds indeed intercalate, or produce DNA damaging radicals) and assays that would investigate specific 
reduction potentials for all synthesized compounds.  
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APPENDICES 
Appendix A 
 
Spectra 1 1H NMR 1,6-Dimethoxyphenazine 
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Spectra 2 13C NMR 1,6-Dimethoxyphenazine 
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                                                      Spectra 3 Mass Spec (ESI) 1,6-Dimethoxyphenazine 
100%MeOH+0.1%HCOOH 15:52:11  19-Apr-2012
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
JARIN_JJ-4_PWANG-ACCU_04-19-2012_ESI-POS01 73 (1.359) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (66:76)
1.12e4241.0969
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
230 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 1-100    H: 1-100    N: 1-15    O: 1-20     
Minimum:                                        -1.5 
Maximum:                    5.0       5.0       50.0 
Mass        Calc. Mass      mDa       PPM       DBE       i-FIT       Formula 
241.0969    241.0977        -0.8      -3.3      9.5       7.9         C14  H13  N2  O2 
  
Spectra 4 1H NMR 1-Hydroxy-6-methoxyphenazine 
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Spectra 5 13C NMR 1-Hydroxy-6-methoxyphenazine 
                                                          Spectra 6 Mass Spec (ESI)
 
 
 
 
 
 1-Hydroxy-6-methoxyphenazine 
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Spectra 7 1H NMR Myxin  
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Spectra 7a 1H NMR 1-Hydroxy-6-Methoxy-N10-Oxide 
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Spectra 8 13C NMR Myxin 
 
  
 
 
 
 
 
Spectra 9 Mass Spec (ESI) Myxin  
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Spectra 10 1H NMR 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide 
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Spectra 11 13C NMR 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide  
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Spectra 12 Mass Spec (ESI) 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide  
 
 
 
 
Jarin_103013_1_131030173851 #573-658 RT: 2.56-2.77 AV: 9 SB: 67 0.58-1.41 , 2.72-3.09 NL: 6.71E7
T: FTMS + p ESI Full ms [180.00-800.00]
320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470
m/z
0
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45
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55
60
65
70
75
80
85
90
95
100
R
e
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a
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v
e
 
A
b
u
n
d
a
n
c
e
371.0928
z=1
435.0057
z=1
366.1382
z=1
428.0538
z=1413.1036
z=1
353.0826
z=?331.1006
z=1 351.0058
z=?
387.0667
z=1 408.1483z=1
419.3137
z=1
394.1686
z=1 441.2941z=1
373.0972
z=1
450.9796
z=1 458.0817z=1338.3400
z=1
355.0869
z=?329.0829
z=1
382.1319
z=2
317.1172
z=?
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Spectra 13 1H NMR 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
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      Spectra 14 13C NMR 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
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Spectra 15 Mass Spectra (ESI) 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide 
 
 
Jarin_103013_2 #415-805 RT: 2.02-3.08 AV: 41 SB: 69 0.58-1.40 , 2.72-3.09 NL: 3.73E7
T: FTMS + p ESI Full ms [180.00-800.00]
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 Spectra 16 1H NMR 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside  
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 Spectra 17 13C NMR 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside 
 
 
 
42 
 
 
 
 
                           
Spectra 18 Mass Spectra (ESI) 6-Methoxyphenazine-1-β-D-tetraacetylgluco-pyranoside 
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Spectra 19 1H NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside 
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           Spectra 20 13C NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside 
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                   Spectra 21 Mass Spec (ESI) 6-Methoxyphenazine-N5-oxide-1-beta-D-tetraacetylgluco-pyranoside 
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      Spectra 22 1H NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside 
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       Spectra 23 13C NMR 6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside  
 
 
 
     Spectra 24 Mass Spectra (ESI) 
 
 
 
 
6-Methoxyphenazine-N5-oxide-1-beta-D-gluco-pyranoside
 
 
 
48 
  
 
49 
 
 
  
             Spectra 25 1H NMR 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside        
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Spectra 26 13C NMR 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside 
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                                               Spectra 27 Mass Spectra (ESI) 6-Methoxyphenazine-1-β-D-tetraacetylgalacto-pyranoside        
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Spectra 28 1H NMR 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside 
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Spectra 29 13C NMR 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside 
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Spectra 30 Mass Spec (ESI) 6-Methoxyphenazine-N5-oxide-beta-D-tetraacetylgalacto-pyranoside 
 
 
 
 
 
